an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: 1. known active acute sars-cov-2 infection ≤ 4 weeks from consent 2. known severe anemia, defined as \< 8 g/dl 3. meeting the following symptom cluster exclusion for all eligible clusters\*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption\*\*, pre-existing sustained severe hypertension (bp\> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if the participant is aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) \*participants who are eligible for \> 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, the participant will be excluded from that individual symptom cluster. \*\* defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 4. known diagnosis of chronic lyme disease with persistent symptoms, sequelae, or related therapy 5. any non-marijuana illicit drug use within 30 days of informed consent 6. current or recent use (within the last 14 days) of study intervention\* 7. known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control\* 8. known contraindication(s) to study intervention(s), 9. inability to discontinue symptomatic medications for the identified time periods 10. moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) 11. currently enrolled in another clinical trial outside this platform protocol or another study intervention appendix in this platform protocol\*\*\* \*\*\*participants may re-enroll in the trial for a different study intervention appendix if the participant has completed an appropriate washout period and efficacy has been determined for the appendix in which the participant was previously enrolled. 12. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study * if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: 1. known active acute sars-cov-2 infection ≤ 4 weeks from consent 2. known severe anemia, defined as \< 8 g/dl 3. meeting the following symptom cluster exclusion for all eligible clusters\*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption\*\*, pre-existing sustained severe hypertension (bp\> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if the participant is aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) \*participants who are eligible for \> 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, the participant will be excluded from that individual symptom cluster. \*\* defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 4. known diagnosis of chronic lyme disease with persistent symptoms, sequelae, or related therapy 5. any non-marijuana illicit drug use within 30 days of informed consent 6. current or recent use (within the last 14 days) of study intervention\* 7. known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control\* 8. known contraindication(s) to study intervention(s), 9. inability to discontinue symptomatic medications for the identified time periods 10. moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) 11. currently enrolled in another clinical trial outside this platform protocol or another study intervention appendix in this platform protocol\*\*\* \*\*\*participants may re-enroll in the trial for a different study intervention appendix if the participant has completed an appropriate washout period and efficacy has been determined for the appendix in which the participant was previously enrolled. 12. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study * if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: known active acute sars-cov-2 infection ≤ 4 weeks from consent known severe anemia, defined as < 8 g/dl meeting the following symptom cluster exclusion for all eligible clusters*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption**, pre-existing sustained severe hypertension (bp> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if the participant is aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) *participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, the participant will be excluded from that individual symptom cluster. ** defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 known diagnosis of chronic lyme disease with persistent symptoms, sequelae, or related therapy any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study intervention* known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control* known contraindication(s) to study intervention(s), inability to discontinue symptomatic medications for the identified time periods moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) currently enrolled in another clinical trial outside this platform protocol or another study intervention appendix in this platform protocol*** ***participants may re-enroll in the trial for a different study intervention appendix if the participant has completed an appropriate washout period and efficacy has been determined for the appendix in which the participant was previously enrolled. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: known active acute sars-cov-2 infection ≤ 4 weeks from consent known severe anemia, defined as < 8 g/dl meeting the following symptom cluster exclusion for all eligible clusters*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption**, pre-existing sustained severe hypertension (bp> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if the participant is aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) *participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, the participant will be excluded from that individual symptom cluster. ** defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 known diagnosis of chronic lyme disease with persistent symptoms, sequelae, or related therapy any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study intervention* known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control* known contraindication(s) to study intervention(s), inability to discontinue symptomatic medications for the identified time periods moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) currently enrolled in another clinical trial outside this platform protocol or another study intervention appendix in this platform protocol*** ***participants may re-enroll in the trial for a different study intervention appendix if the participant has completed an appropriate washout period and efficacy has been determined for the appendix in which the participant was previously enrolled. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: known active acute sars-cov-2 infection ≤ 4 weeks from consent known severe anemia, defined as < 8 g/dl meeting the following symptom cluster exclusion for all eligible clusters*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption**, pre-existing sustained severe hypertension (bp> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if the participant is aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) *participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, the participant will be excluded from that individual symptom cluster. ** defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 known diagnosis of lyme disease any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study intervention* known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control* known contraindication(s) to study intervention(s), inability to discontinue symptomatic medications for the identified time periods moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) enrolled into another study intervention appendix in this platform protocol*** ***participants may re-enroll in the trial for a different study intervention appendix if the participant has completed an appropriate washout period and efficacy has been determined for the appendix in which the participant was previously enrolled. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: known active acute sars-cov-2 infection ≤ 4 weeks from consent known severe anemia, defined as < 8 g/dl meeting the following symptom cluster exclusion for all eligible clusters*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption**, pre-existing sustained severe hypertension (bp> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if the participant is aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) *participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, the participant will be excluded from that individual symptom cluster. ** defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 known diagnosis of lyme disease any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study intervention* known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control* known contraindication(s) to study intervention(s), inability to discontinue symptomatic medications for the identified time periods moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) enrolled into another study intervention appendix in this platform protocol*** ***participants may re-enroll in the trial for a different study intervention appendix if the participant has completed an appropriate washout period and efficacy has been determined for the appendix in which the participant was previously enrolled. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: known active acute sars-cov-2 infection ≤ 4 weeks from consent known severe anemia, defined as < 8 g/dl meeting the following symptom cluster exclusion for all eligible clusters*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption**, pre-existing sustained severe hypertension (bp> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if they are aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) *participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, they will be excluded from that individual symptom cluster. ** defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 known diagnosis of lyme disease any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study intervention* known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control* known contraindication(s) to study intervention(s), inability to discontinue symptomatic medications for the identified time periods moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) enrolled into another study intervention appendix in this platform protocol*** ***participants may re-enroll in the trial for a different study intervention appendix if they have completed an appropriate washout period and efficacy has been determined for the appendix in which they were previously enrolled. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study. refer to appendices for additional appendix-level criteria: known active acute sars-cov-2 infection ≤ 4 weeks from consent known severe anemia, defined as < 8 g/dl meeting the following symptom cluster exclusion for all eligible clusters*: a. cognitive dysfunction: known stroke that resulted in cognitive impairment within 3 months of enrollment b. autonomic dysfunction: atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption**, pre-existing sustained severe hypertension (bp> 180/110 mmhg in the sitting position) c. exercise intolerance: i. any of the following within 4 weeks of consent - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, any acute or chronic disorder that may affect exercise performance ii. if they are aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) *participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, they will be excluded from that individual symptom cluster. ** defined as greater than 2 drinks a day for men and 1 drink a day for women. a drink is equivalent to 12 ounces of beer (5% alcohol content), 8 ounces of malt liquor (7% alcohol content), 5 ounces of wine (12% alcohol content), 1.5 ounces or a "shot" of 80-proof (40% alcohol content) distilled spirits or liquor (e.g., gin, rum, vodka, whiskey). 21 known diagnosis of lyme disease any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study intervention* known allergy/sensitivity or any hypersensitivity to components of the study intervention (s) or control* known contraindication(s) to study intervention(s), inability to discontinue symptomatic medications for the identified time periods moderate or severe immunocompromised patients, such as those described in the nih covid-19 treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/ special populations/immunocompromised/) enrolled into another study intervention appendix in this platform protocol*** ***participants may re-enroll in the trial for a different study intervention appendix if they have completed an appropriate washout period and efficacy has been determined for the appendix in which they were previously enrolled. any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study intervention appendix is open at the time of enrollment. if multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study intervention appendices.

an individual who meets any of the following criteria will be excluded from participation in this study: known active acute sars-cov-2 infection known prior diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome, not related to sars-cov-2 infection known pre-existing dysautonomia, not related to sars-cov-2 infection known stroke within 3 months of enrollment known severe anemia, defined as < 8 g/dl21 meeting the following symptom cluster exclusion for all eligible clusters#: exercise intolerance: participants will be excluded from the symptom cluster if they have had any of the following within 4 weeks of enrollment - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, or any acute disorder that may affect exercise performance; or if they are aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) cognitive dysfunction: participants will be excluded if they have known prior cognitive dysfunction not related to covid-19 autonomic dysfunction: participants will be excluded if they have atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption, pre-existing sustained severe hypertension (bp>180/110mmhg in the sitting position) #participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, they will be excluded from that individual symptom cluster. ɣ defined as greater than 2 drinks a day for men and 1 drink a day for women.22 known diagnosis of lyme disease any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study drug* known allergy/sensitivity or any hypersensitivity to components of the study drug or control* known contraindication(s) to study drug including prohibited concomitant medications and without ability to safely hold prohibited concomitant medications inability to discontinue symptomatic medications for the identified time periods any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study drug appendix is open at the time of enrollment. if multiple study drug appendices are open, a participant may be excluded from any study drug appendix based on contraindications listed in the study drug appendix, current use of study drug, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study drug appendices.

an individual who meets any of the following criteria will be excluded from participation in this study: known active acute sars-cov-2 infection known prior diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome, not related to sars-cov-2 infection known pre-existing dysautonomia, not related to sars-cov-2 infection known stroke within 3 months of enrollment known severe anemia, defined as < 8 g/dl21 meeting the following symptom cluster exclusion for all eligible clusters#: exercise intolerance: participants will be excluded from the symptom cluster if they have had any of the following within 4 weeks of enrollment - an acute myocardial infarction or unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema), acute pulmonary embolism, suspected dissecting aneurysm, severe hypoxemia at rest, or any acute disorder that may affect exercise performance; or if they are aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate) cognitive dysfunction: participants will be excluded if they have known prior cognitive dysfunction not related to covid-19 autonomic dysfunction: participants will be excluded if they have atrial fibrillation or significant cardiac arrhythmia, more than moderate alcohol consumption, pre-existing sustained severe hypertension (bp>180/110mmhg in the sitting position) #participants who are eligible for > 1 cluster must meet all inclusion and no exclusion criteria for an individual symptom cluster. if not, they will be excluded from that individual symptom cluster. ɣ defined as greater than 2 drinks a day for men and 1 drink a day for women.22 known diagnosis of lyme disease any non-marijuana illicit drug use within 30 days of informed consent current or recent use (within the last 14 days) of study drug* known allergy/sensitivity or any hypersensitivity to components of the study drug or control* known contraindication(s) to study drug including prohibited concomitant medications and without ability to safely hold prohibited concomitant medications inability to discontinue symptomatic medications for the identified time periods any condition that would make the participant, in the opinion of the investigator, unsuitable for the study if only one study drug appendix is open at the time of enrollment. if multiple study drug appendices are open, a participant may be excluded from any study drug appendix based on contraindications listed in the study drug appendix, current use of study drug, or known allergy/sensitivity/hypersensitivity and still remain eligible for the remaining study drug appendices.